Previous Article | Next Article 
J Virol, May 1998, p. 3602-3609, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Origin and Rapid Evolution of a Novel Murine
Erythroleukemia Virus of the Spleen Focus-Forming Virus
Family
Maureen E.
Hoatlin,1
Esperanza
Gomez-Lucia,1,
Frank
Lilly,2,
Jay H.
Beckstead,3 and
David
Kabat1,*
Department of Biochemistry and Molecular
Biology1 and
Department of
Pathology,3 School of Medicine, Oregon Health
Sciences University, Portland, Oregon 97201-3098, and
Department of Molecular Genetics, Albert Einstein College of
Medicine, Bronx, New York 104612
Received 21 October 1997/Accepted 28 January 1998
 |
ABSTRACT |
The Friend spleen focus-forming virus (SFFV) env gene
encodes a glycoprotein with apparent Mr of
55,000 that binds to erythropoietin receptors (EpoR) to stimulate
erythroblastosis. A retroviral vector that does not encode any Env
glycoprotein was packaged into retroviral particles and was coinjected
into mice in the presence of a nonpathogenic helper virus. Although
most mice remained healthy, one mouse developed splenomegaly and
polycythemia at 67 days; the virus from this mouse reproducibly caused
the same symptoms in secondary recipients by 2 to 3 weeks
postinfection. This disease, which was characterized by extramedullary
erythropoietin-independent erythropoiesis in the spleens and livers,
was also reproduced in long-term bone marrow cultures. Viruses from the
diseased primary mouse and from secondary recipients converted an
erythropoietin-dependent cell line (BaF3/EpoR) into factor-independent
derivatives but had no effect on the interleukin-3-dependent parental
BaF3 cells. Most of these factor-independent cell clones contained a
major Env-related glycoprotein with an Mr of
60,000. During further in vivo passaging, a virus that encodes an
Mr-55,000 glycoprotein became predominant. Sequence analysis indicated that the ultimate virus is a new SFFV that
encodes a glycoprotein of 410 amino acids with the hallmark features of
classical gp55s. Our results suggest that SFFV-related viruses can form
in mice by recombination of retroviruses with genomic and helper virus
sequences and that these novel viruses then evolve to become
increasingly pathogenic.
 |
INTRODUCTION |
The independently isolated Friend
and Rauscher erythroleukemia viruses (18, 48) are complexes
of a replication competent murine leukemia virus (MuLV) and a
replication-defective spleen focus-forming virus (SFFV) (39, 42,
47). The SFFVs encode Env glycoproteins (gp55) that are
inefficiently processed to form larger cell surface derivatives
(gp55p) (19). The gp55 binds to erythropoietin
receptors (EpoR) to cause erythroblast proliferation and splenomegaly
in susceptible mice. Evidence has suggested that the critical mitogenic
interaction occurs exclusively on cell surfaces (7, 16).
SFFVs are structurally closely related to mink cell focus-inducing
viruses (MCFs) (2, 5, 10, 50), a class of
replication-competent murine retroviruses that has a broad host range
termed polytropic (15, 21). Although MCFs are not inherited
as replication-competent intact proviruses, the mouse genome contains
numerous dispersed polytropic env gene sequences (8,
17, 27). MCFs apparently readily form de novo by recombination
when ecotropic host range MuLVs replicate in mice (14, 15, 26,
43). MCF env genes typically are hybrid recombinants
that contain a 5' polytropic-specific region and a 3'
ecotropic-specific portion (26). They encode a gPr90 Env
glycoprotein that is cleaved by partial proteolysis to form the
products gp70 surface (SU) glycoprotein plus p15E transmembrane (TM)
protein (32, 39, 47). In addition, MCFs often differ from
ecotropic MuLVs in their long terminal repeat (LTR) sequences (8,
20, 26, 28, 29, 45).
Based on their sequences, SFFVs could have derived from MCFs by a
585-base deletion and by a single-base addition in the
ecotropic-specific portion of the env gene (10).
Evidence suggests that both the 585-bp deletion and the frameshift
mutation probably contribute to SFFV pathogenesis (3, 49).
Several pathogenic differences among SFFV strains have also been
ascribed to amino acid sequence differences in the ecotropic-specific
portion of the Env glycoproteins (9, 41).
This report describes the origin and rapid stepwise evolution of a new
SFFV. This new pathogenic virus initially formed in a mouse that had
been injected with an ecotropic strain of MuLV in the presence of a
retroviral vector that does not encode any Env glycoprotein. The mouse
developed erythroleukemia, splenomegaly, and polycythemia after a long
lag phase. At that time the spleen contained viruses with
env genes that were able to activate EpoR. Serial passage of
this initial virus isolate resulted in selection of a novel SFFV that
encodes a gp55 glycoprotein of 410 amino acids. This experimental
system provides a method for isolating new SFFVs and for mapping the
stages in their genesis.
 |
MATERIALS AND METHODS |
Viruses and cells.
Retroviral packaging cell lines
-2
(34) and PA12 (37) were used to produce
helper-free virions encoding EpoR and gp55 by ping-pong amplification
after transfection with retroviral vectors pSFF-EpoRPA11 and pL26K,
respectively, as previously described (6, 29). The
EpoR-encoding virions were used to infect the interleukin-3
(IL-3)-dependent hematopoietic cell line BaF3 (35) to
produce the BaF3/EpoR cells (BER) used in this study as previously described (22). The pL26K retroviral vector encoding gp55 of wild-type SFFV (Lilly-Steeves polycythemic strain) has been described elsewhere (31).
-2 and PA12 cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum BaF3 cells were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 5 × 10
5 M
-mercaptoethanol with 10% WEHI-3 as an IL-3
source. BER cells were maintained in the same medium with
erythropoietin (Epo; Boehringer Mannheim, Indianapolis, Ind.) at 0.5 U/ml instead of IL-3. Preparation of passaged virus from spleens was
described previously (23).
Pathogenic assays.
Helper-free virus encoding wild-type EpoR
was mixed with ecotropic helper virus B4 (38) for injection
as described previously (23). Female NIH/Swiss mice (4 to 8 weeks old) were used for all in vivo pathogenic characterization except
the analysis of Fv-2 restriction. For that study, DBA/2J
(Fv-2s) and the Fv-2rr
congenic strain D2.R were used (13).
Proliferation assays.
For [3H]thymidine
incorporation assays, spleen cells were collected from the spleens of
normal, anemic, and virus-infected mice. Mice were made anemic by
subcutaneous injection of phenylhydrazine hydrochloride (Eastman Kodak,
Rochester, N.Y.) in phosphate-buffered saline (Gibco BRL, Gaithersburg,
Md.) at a dosage of 60 mg/kg for 2 consecutive days (20).
The [3H]thymidine incorporation assay method previously
described by Krystal (30) was used, with slight
modifications. Briefly, spleen cells were resuspended at 8 × 106 cells/ml and then aliquoted into a 96-well plate
containing serial dilutions of Epo. The cells were then incubated for
22 h at 37°C and 5% CO2. Ten microcuries of
[methyl-3H]thymidine (6.7 Ci/mmol; DuPont NEN,
Boston, Mass.) was then added to each well, and the plates were
incubated for 2 h as described above. The reaction was stopped by
addition of trichloroacetic acid (TCA) so that the final concentration
of TCA in the wells was 10%. Adherent cells were dissolved in 0.1 M
NaOH, and the total precipitate was washed three times in 10% TCA. The
pellets were counted in a gamma counter. Colony assays to detect CFU-E (erythroid) were performed using standard methods (25).
Briefly, bone marrow cells taken from femurs and tibias of control and virus-infected mice were suspended in alpha medium (Gibco Laboratories, Grand Island, N.Y.), sedimented by centrifugation, and resuspended in
semisolid medium containing methylcellulose purchased from Terry Fox
Laboratory (Vancouver, British Columbia, Canada) without Epo or in the
presence of 0.5 U of Epo per ml. The cell suspension was plated in
triplicate in 35-mm-diameter Lux dishes (Nunc Inc., Naperville, Ill.)
at 2 × 105 cells/plate. After incubation for 3 days
in a humidified atmosphere containing 5% CO2 at 37°C,
the plates were examined for hemoglobinized bursts. For
factor-independent growth assays, BaF3 cells or BER cells were infected
with passaged virus for 2 h at 37°C in the presence of Polybrene
(8 µg/ml). The cells were pelleted by centrifugation and resuspended
in medium containing growth factor for 48 h. The cells were then
sedimented by centrifugation, washed twice with phosphate-buffered
saline, and resuspended in complete medium without growth factors to
allow for selection of factor-independent cells.
LTBM culture.
Long-term bone marrow (LTBM) cultures were
made by using a modification of the original Dexter LTBM culture method
(12) that allowed for an extended period of erythropoiesis
without addition of Epo to the cultures (36). Bone marrow
cells taken from the tibias and femurs of 6- to 8-week-old female
NIH/Swiss control and virus-infected mice were gently suspended in
Iscove's modified Dulbecco's medium (IMDM; JRH Biosciences, Lenexa,
Kans.), sedimented by low-speed centrifugation, and resuspended in IMDM supplemented with 25% horse serum (ICN Biochemicals, Costa Mesa, Calif.) and with 125 U of penicillin G, 125 µg of streptomycin, and
0.5 µg of hydrocortisone succinate (Sigma, St. Louis, Mo.) per ml.
The combined bone marrow from three mice was plated into three six-well
tissue culture plates (Becton Dickenson, Lincoln Park, N.J.) in a
volume of 3.0 ml/well. After incubation for 1 week at 37°C in a
humidified atmosphere containing 5% CO2, the supernatant
was completely removed and the cultures were reseeded with fresh bone
marrow suspensions prepared as described above. The cultures were
subsequently fed weekly by removing half of the medium and replacing it
with fresh medium.
Western blotting.
For Western blotting, cell lysates were
immunoprecipitated with an anti-Friend MuLV gp70 antiserum that
cross-reacts with Envs encoded by SFFV and MCFs (19, 44, 45)
and electrophoresed on polyacrylamide gels under reducing conditions in
the presence of 1% sodium dodecyl sulfate. The proteins were then
transferred to nitrocellulose membranes, incubated with the same
antibody, and detected with [125I] protein A as described
previously (19, 31).
RT-PCR and DNA sequencing.
Reverse transcription-PCR
(RT-PCR) was performed by standard methods, using total RNA obtained
from the diseased spleens and two primers: forward primer U5
(5'-TCAGCGGGGGTCTTTCATTTG-3'), located in the 5' LTR
(40), and PV3 (5'-CGTTACAGCGGgATCcGGCTAAGC-3'), located in the 3' LTR. Lowercase letters indicate point mutations substituted to create restriction sites for PCR cloning. Either Elongase (Gibco BRL) or PCR SuperMix (Gibco BRL) were used for amplification. PCR products were TA cloned into the pCR 2.1 vector by
using T4 ligase and transformed into INV
F' (Invitrogen, San Diego,
Calif.) as instructed by the manufacturer. Qiagen minipreps were cycle
sequenced with ABI PRISM Dye Terminator (Perkin-Elmer, Branchburg,
N.J.). The sequence was analyzed by using the computer program
MacVector (Oxford Molecular Group, Ltd.). The sequences obtained were
compared to others in the databases by using the BLAST network service
(1).
Nucleotide sequence accession number.
The accession number
for the DE410 sequence is AF030182.
 |
RESULTS |
Origin of a new virus that causes rapid-onset splenomegaly and
polycythemia.
This work was serendipitously initiated by injecting
mice with a nonpathogenic clone of ecotropic Friend MuLV
(38) plus a helper-free preparation of a retroviral vector
(pSFF-EpoRPA11) that encodes wild-type mouse EpoR (see Materials and
Methods). Although a previously made retrovirus that encodes wild-type
EpoR is apparently nonpathogenic, certain EpoR mutations can
constitutively activate its mitogenic signaling to cause leukemia
(33, 51). We reasoned that such activating mutations might
occur in vivo and that pathogenic selection might produce a maximally
mitogenic form of EpoR that would help to define the signal
transduction properties of this hemopoietin receptor (4,
11). Among 11 NIH/Swiss mice injected with this virus, three
developed massive splenomegaly by 62 to 83 days (Table
1). Passaged virus prepared from the
mouse that had splenomegaly and polycythemia at 67 days postinfection
reproducibly caused these symptoms within 2 to 3 weeks in secondary
recipients (Table 1).
Unexpected properties of the newly formed pathogenic virus.
Using RNA, DNA, and protein blotting methods (see Materials and
Methods), we were unable to detect any EpoR-encoding virus in the
enlarged spleens of the initially infected mouse or in the diseased
mice that had been infected with the passaged virus. Furthermore, PCR
amplifications using total RNA and genomic DNAs from these diseased
spleens did not indicate virus-encoded nucleic acids with EpoR
sequences.
We then used an antiserum that is broadly reactive with Env
glycoproteins of MuLVs to search for virus-encoded proteins in
the
original spleen samples from infected mice (Fig.
1). The small
spleen from a mouse
injected only with helper virus contained
a negligible amount of Env
glycoproteins (lane 1). In contrast,
the spleen from the original
67-day mouse with transmissible disease
(Table
1) contained a
relatively large concentration of MuLV
gPr90 and gp70 glycoproteins
plus traces of smaller components,
including one with an apparent
Mr of 60,000 (lane 2). The latter
sample did not
contain a glycoprotein that coelectrophoresed with
gp55 (compare lanes
2 and 3).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 1.
Detection of Env glycoproteins in spleen lysates of
infected mice by immunoblotting. Lysates from spleen cells or cell
lines were immunoprecipitated, run on electrophoresis gels under
reducing conditions, and transferred to nitrocellulose membranes. The
membranes were incubated with anti-Env antibody followed by
[125I]protein A. Lane 1, spleen lysate from a control
animal infected with ecotropic helper virus; lane 2, spleen lysate from
infected day 67 mouse with massive splenomegaly (Table 1); lane 3, cell
lysate from the IP/IR erythroleukemic cell line containing helper-free
SFFV (46).
|
|
Further characterization of the viral disease.
Although
splenic architecture and histology remained normal in mice infected
only with helper virus, the grossly enlarged spleens of mice infected
with the new pathogenic virus lacked recognizable follicles and
appeared to be completely engorged with proliferating erythroblasts and
their differentiating progeny (Fig. 2B
and C). Microscopic examination of fragments from the enlarged spleens
revealed the presence of structures typical of erythroid islands (Fig.
2I). Benzidine staining confirmed the presence of hemoglobin in the
erythroid cells. The livers of these mice also appeared to contain
erythropoietic islands (compare Fig. 2D to Fig. 2E and F), and blood
from these polycythemic mice contained relatively large proportions of
reticulocytes (compare Fig. 2G and H).

View larger version (136K):
[in this window]
[in a new window]
|
FIG. 2.
Pathology consistent with extramedullary erythropoiesis
in infected mice. (A to F) Paraffin-embedded tissue sections stained
with hematoxylin and eosin. Comparable pathology was observed in
animals injected with first- and second-passage viruses, examples of
which are shown here. (A) Normal spleen; magnification, ×214. (B and
C) Virus-infected spleen (magnifications, ×428 and ×857,
respectively) showing loss of normal splenic architecture due to
proliferating erythroid precursors: (D) Liver from helper
virus-injected control mouse; magnification, ×214. (E and F) Liver
from an infected mouse showing erythropoietic foci (arrow);
magnifications, ×428 and ×857, respectively. (G and H) Peripheral
blood smears stained with new methylene blue to detect reticulocytes
(magnification, ×857) from a helper virus-injected control mouse (G)
and an infected mouse showing a striking increase in reticulocytes (H).
(I) Cytocentrifuged cell suspension from an infected mouse spleen
showing an erythroid island composed of macrophages attached to
erythroid precursors; magnification, ×857. A benzidine stain confirmed
the presence of hemoglobin in the immature erythroid cells.
|
|
Although erythropoiesis in normal adult mice is substantially confined
to bone marrows, anemia induces some erythroblast migration
to the
spleens and livers (
20). As shown in Fig.
3B, mice with
phenylhydrazine-induced
anemia had a slight elevation of Epo-dependent
cell proliferation in
cultured spleen cells. In contrast, cells
from the grossly enlarged
spleens of mice infected with the new
virus proliferated at a greatly
amplified rate in an Epo-independent
manner (Fig.
3A).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Proliferation assay of spleen cells from mice
demonstrating amplified Epo-independent growth. Spleen cells from
control mice and two animals infected with first-passage virus were
incubated in serial dilutions of Epo for 22 h followed by addition
of [3H]thymidine for 2 h. The cells were then
assayed for [3H]thymidine incorporation (see Materials
and Methods). (A) Proliferation of spleen cells from infected mice
(solid symbols) compared to that of control spleen cells (open
symbols). (B) Expanded plot of Epo-dependent proliferation of spleen
cells used as controls (i.e., cells from mice injected with
nonpathogenic helper virus and spleen cells from
phenylhydrazine-pretreated and normal mice).
|
|
Bone marrow cells from helper virus-injected control mice and from mice
infected with the new virus were plated in semisolid
medium, and the
plates were examined 3 days later for hemoglobin-containing
bursts. As
shown in Table
2, the burst-forming
erythroblasts
from control mice were Epo dependent, whereas those from
the mice
infected with the new virus were Epo independent.
Preparations of the new virus that had been passaged once in adult
NIH/Swiss mice were tested for their pathogenic activities
in DBA/2J
(
Fv-2s strain) mice compared with the congenic
D2.R (
Fv-2r homozygous) mice. All infected
DBA/2J mice developed palpable
splenomegaly by 2 to 3 weeks, whereas
the D2.R mice reproducibly
did not (Table
3). Thus, like the classical strains of
SFFV,
the new viruses were unable to overcome
Fv-2
resistance.
Effects of the new virus in LTBM cultures.
LTBM cultures are
generally made in stages by first establishing an adherent layer
consisting principally of stromal cells and later adding fresh marrow
onto this stromal support (12, 36). Whenever marrow cells
from mice infected with the new virus were added into cultures that
contained uninfected marrow, nonadherent islands of active
erythropoiesis formed in relatively large numbers (Fig.
4). This did not occur when we used only
bone marrow cells from diseased mice, presumably because the
erythroblasts in these mice had already differentiated and migrated in
vivo to the spleens and livers. Our results suggest that erythroblasts
remain viable in the uninfected long-term cultures maintained without
Epo and that their Epo-independent proliferation and differentiation
are induced by virus after the cultures are seeded with infected cells. In this way, the virus-induced disease appears to be reproduced in cell
cultures.

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 4.
Cytospin preparation of nonadherent cells in LTBM
cultures of normal NIH/Swiss mice after addition of infected bone
marrow. Normal LTBM cultures were recharged with normal bone marrow or
with bone marrow from mice infected with the new virus. First- and
second-passage viruses were examined and found to be comparable.
Nonadherent cells were collected from the medium each week and
examined. The samples shown are cytospin preparations taken from the
cultures 4 weeks after recharge and stained with Wright-Giemsa stain
(magnification, ×428). (A) Normal LTBM culture recharged with bone
marrow from an infected mouse; (B) normal LTBM culture recharged with
normal bone marrow. Benzidine staining for hemoglobin confirmed that
the cells surrounding the central macrophages were erythroid.
|
|
Isolation of distinct new viruses that activate EpoR.
BaF3 is
a line of IL-3-dependent hematopoietic cells, whereas BER is a
derivative that expresses EpoR and can grow in either IL-3 or Epo
(31). The newly formed pathogenic virus (Table 1) and its
progeny that had been passaged in secondary recipient mice were able to
convert BER but not BaF3 cells to factor-independent proliferation,
suggesting that the viruses cause mitogenesis by activating EpoR.
Thereby, we obtained cell lines that contain the EpoR-activating
viruses.
Figure
5 shows a protein immunoblot
analysis of Env-related glycoproteins that were encoded by these
pathogenic viruses. In
agreement with the results in Fig.
1, the spleen
from the 67-day
mouse that originally developed the disease (Table
1)
contained
helper virus-encoded glycoproteins plus a low-abundance
Mr-60,000
component (Fig.
5, lane 1). The
population of factor-independent
cells that formed when BER cells were
infected with passaged virus
1218 contained the
Mr-60,000 component plus a minor proportion
of a
component that comigrated with gp55 (lane 3 in comparison
to the gp55
standard in lane 4). Moreover, after additional in
vivo passages
(passaged virus 429), the virus encoding the gp55
component became
predominant and the
Mr-60,000 component was no
longer evident (lane 2).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
Env glycoproteins in growth factor-independent BER cells
infected with passaged virus. Protein immunoblot methods were as
described for Fig. 1. Lane 1, original spleen lysate from the infected
day 67 mouse; lane 2, BER/passaged virus 429 (second passage); lane 3, BER/passaged virus 1218 (first passage); lane 4, BER/SFFV wild type.
BaF3 cells express an Mr-85,000 protein
(16, 28).
|
|
Sequence analysis of the novel SFFV.
To determine the sequence
of the ultimate virus that encodes an Mr-55,000
protein, an enlarged spleen was obtained from a mouse injected with a
highly passaged preparation of the novel virus. Total RNA was extracted
from the spleen as described in Materials and Methods, and RT-PCR was
performed with the U5-PV3 primer pair. The single amplified band of
approximately 2 kb was TA cloned, and the sequence of the DNA was
determined.
The
env gene sequence of DE410 was highly homologous to the
env sequences of previously studied Friend and Rauscher
SFFVs
and contained the 585-base deletion, a 6-base duplication, and
a
single-base insertion that are characteristic of SFFVs. Figure
6 shows the deduced amino acid sequence
of DE410 in comparison
to the sequences of previously studied gp55s. An
interesting feature
in the new protein sequence is the insertion of an
alanine at
position 167, which results in a length of 410 amino acids.
Although
absent from gp55s of Friend virus strains, this same insertion
occurs in gp55s of Rauscher SFFV (
5) and in endogenously
inherited
retroviral sequences (
26). Features unique to
DE410 include
R47K, I103T, and A353T substitutions (Fig.
6). No changes
in cysteine
residues or potential glycosylation sites were observed.

View larger version (103K):
[in this window]
[in a new window]
|
FIG. 6.
Sequence comparison of the novel SFFV DE410 and several
other SFFVs. In the Clustal W alignment, the sequence of the novel
SFFV, DE410, is compared to the sequences reported by Wolff et al.
(50), Amanuma et al. (2), and Clark and Mak
(10) (GenBank accession no. V01552, J02193, and K00021,
respectively). Amino acid identities are shaded, conservative
substitutions are boxed, and nonconservative differences are shown
without shading. Deletions are shown by dashes. Classical landmarks of
SFFVs are indicated as follows: 1, proline-rich region (approximately
amino acids 235 to 280); 2, the site of the 585-base in-frame deletion
that causes the gp70/p15E cleavage site to be absent in SFFVs; 3, insertion of two leucines caused by a 6-base duplication; 4, site of
the single-base insertion causing a downstream frameshift and early
termination.
|
|
 |
DISCUSSION |
Origin and evolution of a new lineage of SFFV-related
erythroleukemia viruses.
This report documents the origin and
rapid pathogenic evolution of a new lineage of SFFV. This new viral
lineage initially formed after a long latency in an adult female
NIH/Swiss mouse that had been injected with a nonpathogenic,
biologically cloned ecotropic helper MuLV plus a replication-defective
virus that encodes wild-type EpoR. Our expectation was that the latter
virus might mutate in vivo to encode a constitutively active EpoR
derivative and that this virus mutant might cause a leukemia
(33). On the contrary, our results suggest that the
virus-encoded EpoR gene was eliminated or lost by dilution during in
vivo replication and that the pathogenic virus that formed in this
mouse was a recombinant that was able to activate EpoR to stimulate
proliferation and differentiation of infected erythroblasts. When
sacrificed at 67 days, the original mouse contained virus that encodes
a gp60 (Fig. 1, lane 2; Fig. 5, lane 1). After passage of this virus into a secondary recipient, a virus that encodes a gp55 formed. This
gp55-encoding SFFV then rapidly overgrew its progenitors during
subsequent in vivo passages (Fig. 5).
These results have several important implications for our understanding
of murine retroviral leukemogenesis. First, our results
strongly
support the idea that highly pathogenic SFFVs can derive
from less
pathogenic progenitors by a process of in vivo selection.
Second, our
evidence that intermediates in this derivation are
able to activate
EpoR expressed in BER cells also strongly suggests
that the progenitor
viruses have a degree of mitogenic activity.
If these evolutionary
intermediates were nonpathogenic, they would
also not have become
amplified in vivo and their detection and
isolation would have been
much more difficult. Therefore, our
results suggest that
env
genes able to activate EpoR can readily
form during ecotropic MuLV
replication in mice and that the resulting
viruses can evolve to form
SFFVs by a stepwise process of mutation,
recombination, and pathogenic
selection. In this process, successive
intermediates are presumably
increasingly pathogenic. Third, the
fact that we can readily isolate
viruses that activate EpoR by
using BER cells has enabled us to isolate
intermediates in this
evolutionary pathway. Complete characterization
of all intermediates
may eventually provide a detailed understanding of
this lineage
of viruses. Fourth, our results suggest that it may now be
possible
to use BER cells to isolate new lineages of viruses that
activate
EpoR or other hemopoietin receptors.
Although we initiated this study by using a retroviral vector that
encodes EpoR, the EpoR sequences were rapidly deleted and
it seems very
unlikely that they were essential. Rather, we would
anticipate that any
vector that could recombine with endogenously
inherited
env
sequences might suffice to initiate potential SFFV
evolution. Indeed,
we have recently found in collaboration with
J. Portis and colleagues
(Rocky Mountain Laboratories, National
Institute of Allergy and
Infectious Diseases, Hamilton, Mont.)
that our SFF viral vector without
EpoR sequences also readily
and reproducibly participates in generation
of novel SFFVs after
injection with a nonpathogenic helper virus into
newborn mice
(
24). A manuscript describing these results in
detail is in
preparation. In this context, we wish to emphasize that
the pSFF
vector was initially derived from a 5.9-kb SFFV molecular
clone
that had large deletions in its
gag and
pol
regions (
6). The
vector construction involved deletion of
pol-related and polytropic
env sequences and
creation of a multicloning site. Additional
studies will be required to
learn how the sequences of this vector
have participated in formation
of the initial recombinants and
whether other vectors would also
function in this process.
 |
ACKNOWLEDGMENTS |
We are grateful to our colleagues Susan Kozak, Hao Wang, and
Scott Schuetze for help, advice, and encouragement. We are grateful to
Darin Prulhiere, Gerry Segal, and Paula Stenberg for technical assistance.
This research was supported by grants CA 25810 and CA 54149 from the
U.S. National Institutes of Health and by a grant from the Spanish
Ministry of Science and Education.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry and Molecular Biology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Rd., Mailcode L224, Portland, OR 97201. Phone: (503) 494-8442. Fax: (503) 494-8393. E-mail:
kabat{at}OHSU.edu.
Present address: Departmento Patologiá Animal I, Facultad de
Veterinaria, Universidad Complutense, 28040 Madrid, Spain.
Deceased.
 |
REFERENCES |
| 1.
|
Altschul, S.,
W. Gish,
W. Miller,
E. Myers, and D. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[Medline].
|
| 2.
|
Amanuma, H.,
A. Katori,
M. Obata,
N. Sagata, and Y. Ikawa.
1983.
Complete nucleotide sequence of the gene for the specific glycoprotein (gp55) of spleen focus-forming virus.
Proc. Natl. Acad. Sci. USA
80:3913-3917[Abstract/Free Full Text].
|
| 3.
|
Amanuma, H.,
M. Watanabe,
M. Nishi, and Y. Ikawa.
1989.
Requirement of the single base pair insertion at the 3' end of the env related gene of Friend spleen-focus forming virus for pathogenic activity and its effect on localization of the glycoprotein product (gp55).
J. Virol.
63:4824-4833[Abstract/Free Full Text].
|
| 4.
|
Bazan, J. F.
1990.
Structural design and molecular evolution of a cytokine receptor superfamily.
Proc. Natl. Acad. Sci. USA
87:6934-6938[Abstract/Free Full Text].
|
| 5.
|
Bestwick, R.,
B. Boswell, and D. Kabat.
1983.
Molecular cloning of biologically active Rauscher spleen focus-forming virus and the sequence of the long terminal repeat.
J. Virol.
51:695-705.
|
| 6.
|
Bestwick, R. K.,
S. L. Kozak, and D. Kabat.
1988.
Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes.
Proc. Natl. Acad. Sci. USA
85:5404-5408[Abstract/Free Full Text].
|
| 7.
|
Casadevall, N.,
C. LaCombe,
O. Muller,
S. Gisselbrecht, and P. Mayeux.
1991.
Multimeric structure of the membrane erythropoietin receptor of murine erythroleukemia cells (Friend cells). Cross-linking of erythropoietin with the spleen focus-forming virus envelope protein.
J. Biol. Chem.
266:16015-16020[Abstract/Free Full Text].
|
| 8.
|
Chattopadhyay, S.,
M. Cloyd,
D. Linemeyer,
M. Lander,
E. Rands, and D. Lowy.
1982.
Cellular origin and role of mink focus-forming viruses in murine thymic lymphomas.
Nature
295:25-31[Medline].
|
| 9.
|
Chung, S.,
L. Wolff, and S. Ruscetti.
1989.
Transmembrane domain of the envelope gene of a polycythemia-inducing retrovirus determines erythropoietin-independent growth.
Proc. Natl. Acad. Sci. USA
86:7957-7960[Abstract/Free Full Text].
|
| 10.
|
Clark, S., and T. Mak.
1983.
Complete nucleotide sequence of an infectious clone of spleen focus-forming provirus: gp55 is an envelope fusion glycoprotein.
Proc. Natl. Acad. Sci. USA
80:5037-5041[Abstract/Free Full Text].
|
| 11.
|
D'Andrea, A.,
G. Fasman, and H. Lodish.
1991.
Erythropoietin receptor and interleukin-2 chain: a new receptor family.
Cell
58:1023-1024.
|
| 12.
|
Dexter, T.,
T. Allen, and L. Lajtha.
1977.
Conditions controlling the proliferation of heamopoietic stem cells in vitro.
J. Cell Physiol.
91:335-344[Medline].
|
| 13.
|
Dizik, M.,
R. W. Elliot, and F. Lilly.
1981.
Construction of a D2.B6-Fv-2r congenic mouse strain: nonlethality of the homozygous Fv-2r genotype.
J. Natl. Cancer Inst.
66:755-760.
|
| 14.
|
Evans, L. H., and M. W. Cloyd.
1984.
Generation of mink cell focus-forming viruses by Friend murine leukemia virus: recombination with specific endogenous proviral sequences.
J. Virol.
49:772-781[Abstract/Free Full Text].
|
| 15.
|
Famulari, N. G.
1983.
Murine leukemia viruses with recombinant env genes: discussion of their role in leukemogenesis.
Curr. Top. Microbiol. Immunol.
103:75-108[Medline].
|
| 16.
|
Ferro, F.,
S. Kozak,
M. Hoatlin, and D. Kabat.
1993.
Cell surface site for mitogenic interaction of erythropoietin receptors with the membrane glycoprotein encoded by Friend erythroleukemia virus.
J. Biol. Chem.
268:5741-5747[Abstract/Free Full Text].
|
| 17.
|
Frankel, W.,
J. Stoye,
B. Taylor, and J. Coffin.
1989.
Genetic identification of endogenous polytropic proviruses by using recombinant inbred mice.
J. Virol.
63:3810-3821[Abstract/Free Full Text].
|
| 18.
|
Friend, C.
1957.
Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia.
J. Exp. Med.
105:307-318[Abstract].
|
| 19.
|
Gliniak, B., and D. Kabat.
1989.
Leukemogenic membrane glycoprotein encoded by Friend spleen focus-forming virus: transport to cell surfaces and shedding are controlled by disulfide-bonded dimerization and by cleavage of a hydrophobic membrane anchor.
J. Virol.
63:3561-3568[Abstract/Free Full Text].
|
| 20.
|
Hara, H., and M. Ogowa.
1976.
Erythropoietic precursors in mice with phenylhydrazine-induced anemia.
Am. J. Hematol.
1:453-8[Medline].
|
| 21.
|
Hartley, J.,
N. Wolford,
L. Old, and W. Rowe.
1977.
A new class of murine leukemia virus associated with development of spontaneous lymphomas.
Proc. Natl. Acad. Sci. USA
74:789-793[Abstract/Free Full Text].
|
| 22.
|
Hoatlin, M. E.,
F. E. Ferro,
R. W. Geib,
M. T. Fox,
S. L. Kozak, and D. Kabat.
1995.
Deletions in one domain of the Friend virus-encoded membrane glycoprotein overcome host-range restrictions for erythroleukemia.
J. Virol.
69:856-863[Abstract].
|
| 23.
|
Hoatlin, M. E.,
S. L. Kozak,
F. Lilly,
A. Chakraborti,
C. A. Kozak, and D. Kabat.
1990.
Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene.
Proc. Natl. Acad. Sci. USA
87:9985-9989[Abstract/Free Full Text].
|
| 24.
| Hoatlin, M. E., J. Portis, and D. Kabat.
Personal communication.
|
| 25.
|
Humphries, R.,
A. Eaves, and C. Eaves.
1981.
Self-renewal of hemopoietic stem cells during mixed colony formation in vitro.
Proc. Natl. Acad. Sci. USA
78:3629-3633[Abstract/Free Full Text].
|
| 26.
|
Koch, W.,
W. Zimmerman,
A. Oliff, and R. Friedrich.
1984.
Molecular analysis of the envelope gene and long terminal repeat of Friend mink cell focus-inducing virus: implications for the function of these sequences.
J. Virol.
49:828-840[Abstract/Free Full Text].
|
| 27.
|
Kozak, C., and R. O'Neill.
1987.
Diverse wild mouse origins of xenotropic, mink cell focus-forming, and two types of ecotropic proviral genes.
J. Virol.
61:3082-3088[Abstract/Free Full Text].
|
| 28.
|
Kozak, S.,
M. Hoatlin,
J. Ferro F.,
M. Majumdar,
R. Geib,
M. Fox, and D. Kabat.
1993.
A Friend virus mutant that overcomes Fv-2rr host resistance encodes a small glycoprotein that dimerizes, is processed to cell surfaces, and specifically activates erythropoietin receptors.
J. Virol.
67:2611-2620[Abstract/Free Full Text].
|
| 29.
|
Kozak, S. L., and D. Kabat.
1990.
Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production.
J. Virol.
64:3500-3508[Abstract/Free Full Text].
|
| 30.
|
Krystal, G.
1983.
A simple microassay for erythropoietin based on 3H-thymidine incorporation into spleen cells from phenylhydrazine treated mice.
Exp. Haematol.
11:649-660[Medline].
|
| 31.
|
Li, J.-P.,
R. K. Bestwick,
C. Spiro, and D. Kabat.
1987.
The membrane glycoprotein of Friend spleen focus-forming virus: evidence that the cell surface component is required for pathogenesis and that it binds to a receptor.
J. Virol.
61:2782-2792[Abstract/Free Full Text].
|
| 32.
|
Lilly, F.
1970.
Fv-2: identification and location of a second gene governing the spleen focus response of Friend leukemia virus in mice.
J. Natl. Cancer Inst.
45:163-169.
|
| 33.
|
Longmore, G., and H. Lodish.
1991.
An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene.
Cell
67:1089-1102[Medline].
|
| 34.
|
Mann, R.,
R. C. Mulligan, and D. Baltimore.
1983.
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.
Cell
33:153-159[Medline].
|
| 35.
|
Mathey-Prevot, B.,
G. Nabel,
R. Palacios, and D. Baltimore.
1986.
Abelson virus abrogation of interleukin-3 dependence in a lymphoid cell line.
Mol. Cell. Biol.
6:4133-4135[Abstract/Free Full Text].
|
| 36.
|
Mei, R.-L., and S. Burstein.
1991.
Megakaryocyte maturation in murine long-term bone marrow culture: role of interleukin-6.
Blood
78:1438-1447[Abstract/Free Full Text].
|
| 37.
|
Miller, A. D.,
M.-F. Law, and I. M. Verma.
1985.
Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene.
Mol. Cell. Biol.
5:431-437[Abstract/Free Full Text].
|
| 38.
|
Murray, M. J., and D. Kabat.
1979.
Genetic and sialyation sources of heterogeneity of the murine leukemia virus membrane envelope glycoproteins gp69/71.
J. Biol. Chem.
254:1340-1348[Free Full Text].
|
| 39.
|
Ostertag, W.,
C. Stocking,
G. R. Johnson,
N. Kluge,
R. Kollek,
T. Franz, and N. Hess.
1987.
Transforming genes and target cells of murine spleen focus-forming viruses.
Adv. Cancer Res.
48:193-355[Medline].
|
| 40.
|
Purcell, D.,
C. Broscius,
E. Vanin,
C. Buckler,
A. Nienhuis, and M. Martin.
1996.
An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer.
J. Virol.
70:887-897[Abstract].
|
| 41.
|
Ruscetti, S., and L. Wolff.
1985.
Biological and biochemical differences between variants of spleen focus-forming virus can be localized to a region containing the 3' end of the envelope gene.
J. Virol.
56:717-722[Abstract/Free Full Text].
|
| 42.
|
Ruscetti, S., and L. Wolff.
1984.
Spleen focus-forming virus: relationship of an altered envelope gene to the development of a rapid erythroleukemia.
Curr. Top. Microbiol. Immunol.
112:21-44[Medline].
|
| 43.
|
Ruscetti, S. K.,
L. Davis,
J. Feild, and A. Oliff.
1981.
Friend murine leukemia virus-induced leukemia is associated with formation of mink cell focus-inducing viruses and is blocked in mice expressing endogenous mink cell focus-inducing xenotropic viral envelope genes.
J. Exp. Med.
154:907-920[Abstract/Free Full Text].
|
| 44.
|
Ruta, M.,
S. Clarke,
B. Boswell, and D. Kabat.
1982.
Heterogeneous metabolism and subcellular localization of a potentially leukemogenic membrane glycoprotein encoded by Friend erythroleukemia virus.
J. Biol. Chem.
257:126-134[Free Full Text].
|
| 45.
|
Ruta, M., and D. Kabat.
1980.
Plasma membrane glycoproteins encoded by Rauscher and Friend spleen focus-forming viruses.
J. Virol.
35:844-853[Abstract/Free Full Text].
|
| 46.
|
Spiro, C.,
B. Gliniak, and D. Kabat.
1989.
Splenic accumulation of interleukin-3-dependent hematopoietic cells in Friend erythroleukemia.
J. Virol.
63:4434-4437[Abstract/Free Full Text].
|
| 47.
|
Teich, N.,
J. Wycke,
T. Mak,
A. Bernstein, and W. Hardy.
1982.
Pathogenesis of retrovirus-induced disease, p. 785-998.
In
R. Weiss, et al. (ed.), RNA tumor viruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 48.
|
Van Griensven, L., and M. Vogt.
1980.
Rausher "mink cell focus-inducing" (MCF) virus causes erythroleukemia in mice: its isolation and properties.
Virology
101:376-388[Medline].
|
| 49.
|
Watanabe, N.,
M. Nishi,
Y. Ikawa, and H. Amanuma.
1990.
A deletion in the Friend spleen focus-forming virus env gene is necessary for its product (gp55) to be leukemogenic.
J. Virol.
64:2678-2686[Abstract/Free Full Text].
|
| 50.
|
Wolff, L.,
E. Scolnick, and S. Ruscetti.
1983.
Envelope gene of the Friend spleen focus-forming virus: deletion and insertions in the 3' gp70/p15E-encoding region have resulted in unique features in the primary structure of its protein product.
Proc. Natl. Acad. Sci. USA
80:4718-4722[Abstract/Free Full Text].
|
| 51.
|
Yoshimura, A.,
G. Longmore, and H. Lodish.
1990.
Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity.
Nature
348:647-649[Medline].
|
J Virol, May 1998, p. 3602-3609, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gomez-Lucia, E., Zhi, Y., Nabavi, M., Zhang, W., Kabat, D., Hoatlin, M. E.
(1998). An Array of Novel Murine Spleen Focus-Forming Viruses That Activate the Erythropoietin Receptor. J. Virol.
72: 3742-3750
[Abstract]
[Full Text]